New York-based Immunic reported positive topline data from the company’s Phase II EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis (RRMS).
https://www.pharmalive.com/wp-content/uploads/2020/08/Immunics-DHODH-Inhibitor-Hits-Mark-in-Phase-II-Multiple-Sclerosis-Trial-BioSpace-8-3-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-08-03 11:45:442020-08-04 14:02:11Immunic’s DHODH Inhibitor Hits Mark in Phase II Multiple Sclerosis Trial